Galapagos NV
€27.4
187
+€0.2+0.74% Hari ini
Statistik
Harga Tertinggi Hari
27.4
Harga Terendah Hari
27.4
52M Tertinggi
-
52M Terendah
-
Volum
0
Volum Purata
-
Kapasiti Pasaran
1.77B
Nisbah P/E
54.58
Pendapatan Dividen
-
Dividen
-
Akan Datang
Pendapatan
30OctDijangka
EPS yang dijangka
-0.12181143546968001
EPS sebenar
N/A
Orang Lain Juga Mengikuti
Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti GXEA.F. Ini bukan cadangan pelaburan.
Peserta
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
Vertex Pharmaceuticals
VRTX
Kapasiti Pasaran127.99B
Gilead Sciences
GILD
Kapasiti Pasaran98.35B
Abbvie
ABBV
Kapasiti Pasaran346.75B
AMGEN
AMGN
Kapasiti Pasaran179.38B
Regeneron Pharmaceuticals
REGN
Kapasiti Pasaran130.59B
Biogen
BIIB
Kapasiti Pasaran29.83B
Novartis
NVS
Kapasiti Pasaran244.75B
Pfizer
PFE
Kapasiti Pasaran164.39B
Merck
MRK
Kapasiti Pasaran300.25B
Astrazeneca
AZN
Kapasiti Pasaran271.67B
Mengenai
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Show more...
CEO
Dr. Paulus A. Stoffels M.D., Ph.D.
Pekerja
683
Negara
US
ISIN
US36315X1019
WKN
000A0YGNJ